Xbrane Biopharma Full Year 2024 Earnings: Misses Expectations

Xbrane Biopharma (STO:XBRANE) Full Year 2024 Results

Key Financial Results

• Revenue: kr198.7m (down 17% from FY 2023).
• Net loss: kr265.0m (loss narrowed by 18% from FY 2023).
• kr0.21 loss per share (improved from kr11.22 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Xbrane Biopharma Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 39%. Earnings per share (EPS) also missed analyst estimates by 174%.

Looking ahead, revenue is forecast to grow 64% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in Sweden.

Performance of the Swedish Biotechs industry.

The company's shares are up 1.1% from a week ago.

Risk Analysis

You should learn about the 4 warning signs we've spotted with Xbrane Biopharma (including 2 which shouldn't be ignored).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.